SENECA BIOPHARMA INC SNCA 深 滬
已收盤 04-27 16:00:00 美东时间
1.66
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.66
- 總市值 2871.09万
- 52周最高 12015.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2250.00
- 委 比 0.00%
- 總股本 1729.57万
- 歷史最高 5627700.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 2250.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Arrowhead Pharmaceuticals Inks Global Licensing And Collaboration Agreement With Novartis For ARO-SNCA For Synucleinopathies, Such As Parkinson's Disease; Arrowhead Will Receive $200M As An Upfront Payment And Is Eligible To Receive Up To $2B In Milestone Payments Plus Commercial Sales Royalties
Upon closing, Arrowhead will receive an upfront payment of $200 millionNovartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead's preclinical stage siRNA therapy for the treatment of synucleinopathies,
2025-09-02 19:32
INVESTIGATION ALERT: Halper Sadeh LLP Investigates GWPH, COHR, FLIR, SNCA; Shareholders Are Encouraged to Contact the Firm
NEW YORK, NY / ACCESSWIRE / February 9, 2021 /Halper Sadeh LLP, a global invest...
2021-02-10 10:00
Seneca Biopharma (NASDAQ:SNCA) Shares Gap Up to $0.78
Seneca Biopharma, Inc. (NASDAQ:SNCA) shares gapped up before the market opened ...
2020-12-19 11:50
SHAREHOLDER ALERT: WeissLaw LLP Investigates Seneca Biopharma, Inc.
NEW YORK,Dec. 17, 2020/PRNewswire/ -- WeissLaw LLPis investigating possible bre...
2020-12-18 03:51
Seneca Biopharma宣布有关治疗缺血性中风的中国II期临床研究完成
马里兰州日耳曼敦2020年9月10日 /美通社/ -- 专注于为医疗需求尚未得到满足的疾病开发新疗法的生物制药公司Seneca Biopharma, Inc....
2020-09-10 20:00
Seneca Bio down 12% after pricing stock offering
Nano cap Seneca Biopharma (SNCA-11.8%) slumps out the gate in reaction to its d...
2020-05-22 21:34
Seneca Biopharma Q1 EPS $(0.930) Up From $(3.420) YoY, Sales $6.020M Up From $2.500K YoY
Seneca Biopharma (NASDAQ:SNCA) reported quarterly losses of $(0.930) per share....
2020-05-15 20:05
Seneca Biopharma reports Q1 results
Seneca Biopharma (NASDAQ:SNCA): Q1 GAAP EPS of -$0.93. Revenue of $6.02K (+140....
2020-05-15 12:05
Seneca Biopharma公布二期临床试验的最新消息
这项二期试验目前正在中国进行，旨在治疗缺血性中风 马里兰州日耳曼敦2020年4月11日 /美通社/ -- 专注于开发全新疗法从而治疗医疗需求在很大...
2020-04-11 01:02
Seneca Biopharma宣布与FDA的会议结果
会议主题是肌萎缩性脊髓侧索硬化症疗法NSI-566三期临床试验的设计 马里兰州日耳曼敦2020年4月9日 /美通社/ -- 专注于开发新疗法治疗那些医疗需求严重...
2020-04-09 20:00
